These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26275900)

  • 21. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
    Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
    Yates T; Haffner SM; Schulte PJ; Thomas L; Huffman KM; Bales CW; Califf RM; Holman RR; McMurray JJ; Bethel MA; Tuomilehto J; Davies MJ; Kraus WE
    Lancet; 2014 Mar; 383(9922):1059-66. PubMed ID: 24361242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
    Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
    Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
    Preiss D; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Leiter LA; Mazzone T; Rutten GE; Tognoni G; Martinez FA; Chiang FT; Califf RM; McMurray JJ
    BMJ Open; 2012; 2(6):. PubMed ID: 23204139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An outcome model approach to transporting a randomized controlled trial results to a target population.
    Goldstein BA; Phelan M; Pagidipati NJ; Holman RR; Pencina MJ; Stuart EA
    J Am Med Inform Assoc; 2019 May; 26(5):429-437. PubMed ID: 30869798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
    Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K;
    Lancet; 2009 May; 373(9675):1607-14. PubMed ID: 19395079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
    Schatz H; Schoppel K; Lehwalder D; Schandry R
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
    Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.
    Apovian CM; Bergenstal RM; Cuddihy RM; Qu Y; Lenox S; Lewis MS; Glass LC
    Am J Med; 2010 May; 123(5):468.e9-17. PubMed ID: 20399326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
    Tomono S; Uchiyama T; Ohyama Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
    [No Abstract]   [Full Text] [Related]  

  • 34. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK; Sibal L; Ashwell SG; Home PD
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry.
    Golwala H; Pandey A; Ju C; Butler J; Yancy C; Bhatt DL; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2015 Aug; 66(8):917-26. PubMed ID: 26293762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension Management in Diabetic Kidney Disease.
    Patney V; Whaley-Connell A; Bakris G
    Diabetes Spectr; 2015 Aug; 28(3):175-80. PubMed ID: 26300610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.
    Lewis EF; Claggett B; Parfrey PS; Burdmann EA; McMurray JJ; Solomon SD; Levey AS; Ivanovich P; Eckardt KU; Kewalramani R; Toto R; Pfeffer MA
    Am Heart J; 2015 Aug; 170(2):322-9. PubMed ID: 26299230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.
    Khazanie P; Heizer GM; Hasselblad V; Armstrong PW; Califf RM; Ezekowitz J; Dickstein K; Levy WC; McMurray JJ; Metra M; Tang WH; Teerlink JR; Voors AA; O'Connor CM; Hernandez AF; Starling R
    Am Heart J; 2015 Aug; 170(2):290-7. PubMed ID: 26299226
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.